Atrial Natriüretik Peptidler

Year 1987, Volume: 40 Issue: 3, 225 - 244, 30.09.1987

Murat Turgay

https://izlik.org/JA78SB77RU

Abstract

Atriyum kardiyositlerinden salınan ANP'nin dolaşımdaki major hormonal formu 28a.a.'li ANP (Ser 99-Tyr 126) dır. ANP'nin etkilediği primer hedel organ böbreklerdir. ANP, glomerüler titrasyon hızını artırır, renal kan akımını medulla ve korteksin iç kısımlarına yöneltir. Glomerüllerde ANP için spesifik bağlanma alanları gösterilmiştir. cGMP, ANP'nin glomerüler fonksiyonunda aracı olarak görev yapmaktadır. ANP'nin natriüresis ve diüresis oluşturmasında iç meüuller
toplayıcı kanallar üzerindeki etkisi de suçlanmaktadır. ANP plazma düzeyleri, konjestif kalb yetmezliğinde, kronik böbrek yetmezliğinde, esansiyel hipertansiyonda, sirozda,paroksismal taşikardide ve yanıkta artarken, Bartter sendromu ve Gordon sendromunda azalmaktadır. Yine, sıçan zona glomerülosa hücre kültürlerinden aldosteron salınımını inhibe etmektedir.
ANP, peptid yapısında olduğundan mide sıvısında harab olur. ANP'nin klinikte kullanılabilmesi için sentetik analoglarının yapılması gereklidir. Bu suretle de oral yolla verilip emilebilmelidir. Bu konuda yeni çalışmalar, yeni yeni bilgiler ve klinik yaklaşımları ortaya çıkaracaktır.

Keywords

ANP prekürsörü , MİYOENDOKRİN HÜCRELERİ , ATRİAL NATRİÜRETİK PEPTİDLER

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

Atrıal Natrıuretıc Peptıdes

https://izlik.org/JA78SB77RU

Abstract

The major hormonal form of ANP released from atrial cardiocytes in circulation is 28a.a. ANP (Ser 99-Tyr 126). The primary target organ affected by ANP is the kidneys. ANP increases the glomerular titration rate and directs renal blood flow to the inner parts of the medulla and cortex. Specific binding sites for ANP have been demonstrated in the glomeruli. cGMP acts as a mediator in the glomerular function of ANP. The effect of ANP on the inner meuler collecting ducts is also blamed for the formation of natriuresis and diuresis. ANP plasma levels increase in congestive heart failure, chronic renal failure, essential hypertension, cirrhosis, paroxysmal tachycardia and burns, while decreasing in Bartter syndrome and Gordon syndrome. Again, it inhibits aldosterone release from rat zona glomerulosa cell cultures. Since ANP has a peptide structure, it is destroyed in gastric fluid. In order for ANP to be used in the clinic, synthetic analogues must be made. In this way, it must be administered orally and absorbed. New studies on this subject will reveal new information and clinical approaches.

Keywords

ANP precursor , MYOENDOCRINE CELLS , ATRIAL NATRIURETIC PEPTIDES

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1, Kisch B. : Electon microscopy of the âtrium of the heart. I. Guinea pig. EzP. Med Surg. 14, 99-112, 1956.
• 2. Palate GE. : Secterory granules in thö atrial myocardium, Anat. Rec. 130, 262- 268, 1961.
• 3. Jemlieson JD, Palade GE. - Specific granules in atrial muscle celis. J. Cell Biol, 23, 151-162, 1904.
• 4. Forsmann WG, Giardier LA. : Study of T system in rat heart, J. Cell Bio 44, 1-44, 1970.
• 5. Mec Nutt NS, Fawcett DW.,: The ulirastucture of the cat myocardiur, II, Atrial muscle. J. Cell Biol, 42, 46-47, 1969.
• 6. Rencesme SA, Berger JM. : Speçific granules in mammalian and non-mammalan vertebrate cardiacytes. In : Bajusz E and Jasmin G, eds Meth Achievm exp Path. Basel; Karger 5, 173-213, 1971.
• 7. Reinecke M, Nehis M, Forsmann WG, : Phylogenetic aspects of cardiac hormones âs revsaled by immünocytochemistry, electronmicroscopy and bioassay. Peptides 6 suppl 3, 321-31, 1985,
• 8. Huet M, Cantin M. : Ultrastructural cytochemistry of atrial muscle celis. Tl. Characterization of the protein content of specific granules. Lab Invest. 30, 525-532, 1974. 9. Huet M, Benehimol 5S, Berlinguet JC, Castonguay Y, Cytochiminie ultrastructurule des cardiocytes de Voreillette humaine. 4, Digestion des granules spöcifigüues par les proteases. / Microscopie (Paris) 21, 147-58, 174,
• 10. Marie JP, Guillemot H, Hatt PY. Le degre de granuletion des cardicoytes auricularies, Etude planimetrigue au cours de coürş de differents apports d'eau et de sodium chez le rat. Path Biol. 24, 549-54, 1976.
• 11. De Bold AJ, Rorenstein HB, Verss AT, Sonnenberg HA. A rapid and potent natriuretic response to intravenous enjection of atrial extracts in rats. Life Si. 28, 88-94, 1981.
• 12. Henry JP, Gauer OH, Reevöş JL. Evidens of the atrial location of receptors influencing urine flow. Circulation Res, 4, 85-90, 1956.
• 13. Linden. RJ, Steehan N. Humoral natüre of the urine response to stimulation of atril receptors. Ouart J Exp Physiol, 46, 431-8, 1981.
• 14. Fiynn TG, De Bold ML, De Bold AJ, : The amino &cid seguence of an airial peptide. with potent diuretic and natriuretic properties. Biçchem Biophys Res Commun. 117, 8590-65, 1988.
• 15. Forsmann WG, Hock 1, Lottspaioh F, Henscheh A, Kreye V, Chistmann M, Reinecke M, Metz J, Carlguist M, Mutt V. : The right auricle of the heart is an endocrine organ, Cardiodilatin as a peptide hormone candidate, Anat Embyol, 168, 307-13, 1983.
• 16. Currie MG, Sukin D, Geller DM, Cole ER, Negâleman P. : Atriopeptin release from the isolated perfused rabbit heart. Biochem Biophys Res Commumn. 124, 711-7, 1984.
• 17. Thibault G, Garcia R, Gutkowska J et al. : Identification of the released form of atrial natriuretic factorhy the perfuzed rat heart. Proc Soc Exp Biol Med, 182, 137, 1988.
• 18. Tripnedo NC, lanuszewicz A, Pegram BL, et al, : Rat platelets activile high molecular weight atrial natriuretic peptide in vitro. Hypertension, 7, 905-12, 1985,
• 19. Tiynn TG, Davies PL, Kennedy BP, De Bold AJ. : Alingment of rat cardionairin seğguences with the precardionaitrin seguence İrom complementary DNA. Seiende, 228, 323-5 1985,
• 20. Geller DM, Currie MG, Siegel NR, Adams SP, Negdleman P, : The seguence of an atriopeptigen : a precurşor of the bicactive atrial peptides. Biochem Biophys Res Commun, 121, 802-7, 19RA4,
• 21. Formanın WG, Birr GC, Christmann M, Finke R, Henschen A, Hock D, Kirchheim H, Kreye V, Lottspeich F, Metz J, Mutt J, Reinecke M. : The auricular yocardiocytes of the heart costitute an endocrine organ. Characterization ci a porcine cardiac peptide hormone. cardiodilatin-125, Cell Tissue Res 238, 425-30, 1984.
• 22. Kangawa, K, Fukuda A, Minamino N, Maisuo H. : Purification and complete amino âcid söguence of beta-rat atrial natriuretic polypeptide (betarrANP) of 5000 Daltons. Biochem Biophys Res Corumun 119, 933-40, 1984.
• 23. Sagnella GA, Shore AC, Mackando ND, Mac Gregor Ga. : Effects öf changes in dietary sodium intake and saline infusion on imınunoreactive girial nalriuretic peptide in human plasma. Lancet 2, 1208-11, 1985.
• 24. Espiner EA, Nicholls MG, Yandle TG, et al. ; Studieson the secretion, metabolism and action of atrial natriuretiç antğk in man. J. Hypertension 4 isuppy 2), 5 85-91, -980.
• 25. Sagnella GA, Shore AC, Markandu ND, Mac Gregor GA, : Raised circulating levels gf atrial natriuretic peptides in essenlial hypertension. Lancet 1, 178-8), 1986.
• 26. Canepa-Anson R, Williams M, Marchali J Mitsuoke T, Lightman Ş, Sutter R. : Mochanism of polyuria and natriuresis in atrıoventricular nodal tachycardia. Br. Med J 286, 866-868, 1984.
• 27. Shifirin EL, Gutkowska J, Kuchel O, Cantın M, Genest J. : Plasma concentraton of atrial natriurstic factor in a patient with paroxysmal atrial tachycardia. New Engel J.Med 312, 1196-1197, 1985,
• 28. Braguet M, Carsin H, Guilbaud J, Chabrier E, Viossat I. Braguet P. : Plasma atrial natriuretic peptide in severe (hermal injury , Lancet 23, 486, 1986.
• 29. Hodsman GP, Tsunoda K, Ogawa K, Johnton CI, ; Effects of posture on circulating atrial natriuretic peptide. Lancet 21/28, 1427, 1985.
• 30. Donekier J, Anderson JV, Yeo T, Bloom SR. : Diurnal rytlım in the plasma concentration of atrial natriuretic peptide, NEJM, 11, 710, 1986.
• 31. Marie-France D, Pepersack T, Abramow M. : Hing plasma levels of atrial natriuüretic factor in SIADH, NEJM, 8, 1258, 1986.
• 32. Relang, Tunger, Dranten. : Alfâ-atrial natriuretic peptide concentrations in plasma of children with congenital heart and pulmonary diseases. British Medical J. 292,9, 1241, 1985.
• 33. Shionori H, Kaneko Y. : Intranasal administration of alpha human natriuretic peptide produces a prolonged diuresis in healthy man. Life Sci. 38, 773-8, 1988.
• 34. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. : Metabolic clearence rate and plasma half life or alpha-human atrial nairiuretic peptide in man. Life Sci. 38, 1837-38, 1986.
• 35. Anderson J, Struthers A, Christofides N, Bloom 5S, : Atrial natriuretic peptideğ; an endogenous factor enhancing sodium excretion in man, Clin Sci. 70, 327-31, 1988.;
• 36. Tikkanen 1, Mesarinne K, Fyhrguist F, Leidenius R. : Plasma atrial natriuretic peptide in cardiac disease and during infusion in healty volunteers. Lancet, -2, 66-9, 1985.
• 37. Weidmann P, Gnadinger MP, Ziswiler HR. et al. : Cardiovascular, endocrine and renal effect of atrial natriuretic peptide in essential hypertension. J Hypertension 4 (suppl 2), S 71-83, 1986.
• 38. Cody RJ, Covit AB, Larangh JH, Awlas $. : Atrial natriuretic factor (ANF ) in normal men : renal hemodynamic/hormonal responses. Hypertension. 7, 845, 1985.
• 39. Keeler AR, Azzorolo AM. : Effects of atrial naitriuretic factor on renal handling of water and elecirolytes in rats. Can J Physiol Fharmacol 61, 996-1002, 1983.
• 40. Hariter Eweisel M, Stummvoll HK, Wolosozuk W, Punzengruber C, Ludvik B. : Atrial natriuretic peptide concentrations in bloodfrom right atrium in patient with severe right heart failure. Lancet 2, 96, 1285.
• 41. Burnett JC, Granger JP, Opgenorth TE. : Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 247, F 863-866, 1984.
• 42. Borenstein HB, Cupples WA, Sonnenberg HA, et al. : The effects of nâiriuretic peptide on renal haemodynamics and urinary excretion in anaesthetized rats. J. Physiol (Lond) 334, 133-140, 1983.
• 43. Ichikawa I, Dunn BR, Troy JL, et al. ; Influence of atrial natriuretic peptide on glomeruler microcirculation in vivo. Clin Res 33, 437 A, 1985.
• 44. Friend TA, Mc Coy AM, Osgood BW, etal.: Effeci vi siriopeplin 1! on delerminents of glomerüler ultrafiltration rate in the in vitro perfuscd dog glomerulus. Am J Physiol 250, F 1119-F 1122, 1988.
• 45. Koseceki C, Hayaski Y, Torikai S et al. : Localization of binding sites Tor rat atrişl natriuretic polypeptide in rat kidney. Am J. Physiol, 250, F 210-F 216, 1986.
• 46. Ballerman BJ, Hoover RL, Karnovsky MJ, Brenner BM, Physiologic regulation of atrial natriuretic peptide receptors in rat renal glomeruli. J Clin Invest 76, 2049-56, 1985, j
• 47. Bianhi C, Gutkowska J, Thibault G, Garcia R, Genest J, Cantin M. : Radioautographic localization of 125 Latrial natriuretic factor (ANF) in rat tissues, Histochemisiry 82, 441-52, 1985.
• 48. Bellerman BJ, Brenner BM. : Physiolgicaliy reğulated atrial npiriuretic peptide receptors in renal glomeruli. Trans Assoc Am Physicians 98, 92-100, 1985.
• 49. Burnett JC, Granger JP, Opgeneorth TJ, : Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 247, F 863-F 866, 1984.
• 50. Hammond 'T, Yusufi ANK, Knox FG. etal: Adminisireilon o! atrial natriuretic factor inhibits sodium-çoupled transport in proximal tubules. J Clin Invest. 75, 1983-89, 1985.
• 51. Cogan MG. : Atrial natriuretic factor can increase renal solute excretion primarily by raising glomeruler filtration. Am J Physial 250, F 710-714, 1986.
• 52. Baum M, Toto RD. : Lack of a direct effect of atrial natriuretic factor in the rabbit proximal tubule, Am J Physiol 250, F 66-69, 1986.
• 53. Kondo Y, İmai M, Kangawa K et al. : Lack of direct action ol human airial nat riuretic polypeptide on the in vitro perfused segmenis of Henle'şs loop isolated from rabbit kidney. Pflugers Arch 406, 273-278, 1886.
• 54. Dillingham MA, Anderson RJ. ; İnhibitlon of Vasopressin action by airial natriuratic factor. Science 231, 1572-73, 1986.
• 55. Sonnenberg H, Cupples WA, D Bold AJ, et al. : Intrarenal localition of the natriuretic effects of cardiac atrial extract, Can J Physiol Pharmacol, 60, 1149- 1152, 1882.
• 56.Zeidel ML, Seifter JL, Brenner BM, et al. : Trial peptides inhibit O, consumption in rabbit renal medullary collecting duct cells. Am J Physiol 251, F 378-F 383, 1986.
• 57. Trippodo NC, Kardon MB, Pegram BL, Cole FE, MacPhee AA, : Acute haemodynamie effects of the atrial nairiuretic hormone in rats. J Hypertension 4 (suppl 2), S 35-40, 1986.
• 58. Atlas S. : Atrial natriuretic factor : a new hormone of cardiac origin. Recent Prog Horm Res 42, 207-490, 1986.
• 59. Biollaz J, Nussberger J, Waeber B, Brunner HR. Clinical pharmacology of atrial natriuretic (3-28) gicosahexapeptide. J Hypertension 4 (suppl 2), s 101-8, 1986.
• 60. Breuhaur BA, Saneli HH, Brandt MA, Chimoskey JE. Atriopeptin II lowers cardiac output in conscious sheep. Am J Physiol 249, R 776-80, 1985.
• 61. Chartisr L, Khibault G; Garcia R, Schifirin EL. Atrial natriuretic factor inhibits the effects of angiotensin II ACTH and potassium on pldosterone section by isolated rat adrenal glomerulosa cells. Proceedings of the 7th Congress of Endocrinology, Guehec Canada 1984, p. 410,
• 62. Samson WK, Atrial natriuretic fâctor inhibits dehydration and hemorrhage-induced vasopressin release. Neuroendocrinology 40, 277, 1985.
• 63. Jauszewics P, Gutkowska J, De Lean A et pl. Synthetic atrial natriuretic factor İnduce release (possibly receptor-mediated) of vasopreşsin İrom ral posterlor pitultary. Proc Soc Exp Biol Med 178, 321, 1985.
• 64. Guirion R, De Lean A, Gutkowska J. Cantin M, Genest J. Receptors/aceptors for atrial natriuretic factor (ANF) in brain and related structures. Peptidea 5, 1167, 1984.
• 65. Schiffrin EL, Chartier L, Thibault G, Si-Louis J, Cantin M, Genest J, Vascular and adrenal receptors for atrial natriuretic factor in the rat, Ciro Res 56, 801-7, 1985.
• 66. Winguist RJ, The relaxant effect of atrial factor on vascular smooth muscle. Life sci 37, 1081-7, 1985.
• 67. Schafferhans K, Heidbreder E, Grimm D, Heidland A. Norepinephrine-induced acute renal failure. Benelicial effects ol atrial natriuretic factor. Neplıron 44, 240-244, 1986,
• 68. Hasegawa K, Matsushita Y, moue T, Mori H et al. Plasma levels of atrial natriuretic peptide in patients with chronic renal failure. J Clin Endocrinol Metab 63, 819, 1986.
• 69. Rascher W, Tulassay T, Lang Re. Airial natriuretic peptide in plasma of volume- overloaded children with chronic renal failure. Lancet 2, 303, 1985,
• 70. Sugawa A, Nakao K, Sakamoto M, et al. Plasma concentration of atrial nat riuretic polypeptide in essential hypertension. Lancet 2, 1426-27, 1985,
• 71. Sagnella GA, Markandu ND, Shore AC, MacGregor GA, Raised cirçculating levels of atrial natriuretic peptides in essential hypertension. Lancet 1, 179-181, 1988.
• 72. Shikuma R, Kambara S, et al, Dopaminergic modulation of salt sensitivity in essential hypertension. Nippon Jinzo Gakkai, 26, .417-23, 1984,
• 73. MacDonald TM, Jeffrey RF, Lee MR. Atrial nairiuretic peptides in essential hypertension. Lancet 8, 562, 1986.
• 74. Takkanen L, Fhyhrguist F, Metsarinne K, Leldenius F. Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. Lancet 2, 66-69, 1985.
• 75. Nakaoka H, Imataka K, Fujii J, Ishibashi M, Yamaji T. Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med, 313, B92-03, 1085.
• 76. Kouz 5, Bourrassa MG, Laurier J et al, Plasma concentrations of immunoreactive atrial natriuretiç factor in patients with coronary heart disease (abst) 35 th Annual scientific session, American College of Cardiology, March 9, 1986, Atlanta, Georgia.